Related references
Note: Only part of the references are listed.Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Aaron C. Tan et al.
LUNG CANCER (2020)
Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.
Kirstin Perdrizet et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PPM5 COSTS OF IN-HOUSE MUTATIONAL-TESTING AND IMPLICATIONS FOR ECONOMIC EVALUATION: A CASE EXAMPLE OF NON-SMALL CELL LUNG CANCER (NSCLC)
J. Nam et al.
VALUE IN HEALTH (2019)
Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer
James Signorovitch et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Simon Garinet et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer
Mikyung Kelly Seo et al.
PLOS ONE (2018)
Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions
Kathryn A. Phillips et al.
VALUE IN HEALTH (2018)
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing
Brett Doble et al.
LUNG CANCER (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis A Report of the Association for Molecular Pathology
Linda M. Sabatini et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)
Gilberto De Lima Lopes et al.
Journal of Thoracic Oncology (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials
James H. Suh et al.
ONCOLOGIST (2016)
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
Kim M. Hirshfield et al.
ONCOLOGIST (2016)
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Siraj M. Ali et al.
ONCOLOGIST (2016)
Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment?
Juliette Plun-Favreau et al.
PUBLIC HEALTH GENOMICS (2016)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Clinical application of high-throughput genomic technologies for treatment selection in breast cancer
Aaron R. Hansen et al.
BREAST CANCER RESEARCH (2013)
Genetic Changes in Squamous Cell Lung Cancer A Review
Rebecca S. Heist et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Share Paper
